MicroRNA expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy in metastatic melanoma treated on the ECOG-ACRIN trial E2603

Correlation of Somatic Mutations and Clinical Outcome in Melanoma Patients Treated with Carboplatin, Paclitaxel, and Sorafenib

(2014) M. A. Wilson et al.   CLINICAL CANCER RESEARCH

Nfix is a novel regulator of murine hematopoietic stem and progenitor cell survival

(2013) P. Holmfeldt et al.   BLOOD

A regulatory circuit that involves HR23B and HDAC6 governs the biological response to HDAC inhibitors

(2013) M New et al.   CELL DEATH AND DIFFERENTIATION

Nuclear Factor One X Regulates Bobby Sox During Development of the Mouse Forebrain

(2013) Chantelle Dixon et al.   CELLULAR AND MOLECULAR NEUROBIOLOGY

Conserved and divergent functions of Nfix in skeletal muscle development during vertebrate evolution

(2013) A. Pistocchi et al.   DEVELOPMENT

Epigenomic enhancer annotation reveals a key role for NFIX in neural stem cell quiescence

(2013) B. Martynoga et al.   GENES & DEVELOPMENT

The Role of Altered Nucleotide Excision Repair and UVB-Induced DNA Damage in Melanomagenesis

(2013) Timothy Budden et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

RAC1: An Emerging Therapeutic Option for Targeting Cancer Angiogenesis and Metastasis

(2013) H. K. Bid et al.   MOLECULAR CANCER THERAPEUTICS

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

In-Depth Characterization of microRNA Transcriptome in Melanoma

(2013) James Kozubek et al.   PLoS One

BIOMARKER SIGNATURE IDENTIFICATION IN “OMICS” DATA WITH MULTI-CLASS OUTCOME

(2013) Vincenzo Lagani et al.   Computational and Structural Biotechnology Journal

Differential expression of microRNAs during melanoma progression: miR-200c, miR-205 and miR-211 are downregulated in melanoma and act as tumour suppressors

(2012) Y Xu et al.   BRITISH JOURNAL OF CANCER

RhoJ Regulates Melanoma Chemoresistance by Suppressing Pathways That Sense DNA Damage

(2012) H. Ho et al.   CANCER RESEARCH

A Landscape of Driver Mutations in Melanoma

(2012) Eran Hodis et al.   CELL

Histology-Specific MicroRNA Alterations in Melanoma

(2012) Laura Poliseno et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

(2012) Axel Hauschild et al.   LANCET

Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma

(2012) Michael Krauthammer et al.   NATURE GENETICS

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Routine Multiplex Mutational Profiling of Melanomas Enables Enrollment in Genotype-Driven Therapeutic Trials

(2012) Christine M. Lovly et al.   PLoS One

The diverse roles of Rac signaling in tumorigenesis

(2011) Natalie A. Mack et al.   CELL CYCLE

Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032)

(2011) Poulam M. Patel et al.   EUROPEAN JOURNAL OF CANCER

Prognostic and Clinicopathologic Associations of OncogenicBRAFin Metastatic Melanoma

(2011) Georgina V. Long et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

mirConnX: condition-specific mRNA-microRNA network integrator

(2011) G. T. Huang et al.   NUCLEIC ACIDS RESEARCH

Signatures of MicroRNAs and Selected MicroRNA Target Genes in Human Melanoma

(2010) D. Philippidou et al.   CANCER RESEARCH

Melanoma MicroRNA Signature Predicts Post-Recurrence Survival

(2010) M. F. Segura et al.   CLINICAL CANCER RESEARCH

Plexin B1 Suppresses c-Met in Melanoma: A Role for Plexin B1 as a Tumor-Suppressor Protein through Regulation of c-Met

(2010) Laurel Stevens et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Downregulation of miR-125b in metastatic cutaneous malignant melanoma

(2010) Martin Glud et al.   MELANOMA RESEARCH

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy

(2010) O. Khan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

MicroRNAs and cancer epigenetics: a macrorevolution

(2009) Veronica Davalos et al.   CURRENT OPINION IN ONCOLOGY

Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma

(2009) Axel Hauschild et al.   JOURNAL OF CLINICAL ONCOLOGY

Loss-of-Function Fibroblast Growth Factor Receptor-2 Mutations in Melanoma

(2009) Michael G. Gartside et al.   MOLECULAR CANCER RESEARCH

Plexin B1 is repressed by oncogenic B-Raf signaling and functions as a tumor suppressor in melanoma cells

(2009) G M Argast et al.   ONCOGENE

Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia

(2008) Rosa Rademakers et al.   HUMAN MOLECULAR GENETICS

Patterns of Persistent DNA Damage Associated with Sun Exposure and the GlutathioneS-transferase M1 Genotype in Melanoma Patients

(2008) Mark L. Steinberg et al.   PHOTOCHEMISTRY AND PHOTOBIOLOGY